Bruce Booth
@LifeSciVC
Followers
54K
Following
23K
Media
631
Statuses
12K
Early stage biotech VC. Recovering scientist. Opinions expressed are solely my own and do not express the views or opinions of Atlas Venture.
Cambridge, MA
Joined December 2010
$FOLD IPO'd in May 2007 with a valuation of $320M. Bought today for over $4.8B. 15x+ increase in value. But the IPO price was $15.00... and the acquisition price is $14.50. Nearly 95% dilution in 18 years. It's a tough business. That said, if you bought $FOLD in spring of
3
3
28
On today’s final 2025 episode of #BiotechHangout, @daphnezohar, @LifeSciVC, & @EricSchmidt151 will cover general market overview: companies ($IMNM & $KYTX) raising cash after data w/weak post-deal performance – trend or pre-holiday fatigue?, @LifeSciVC’s year in review &
0
4
11
Biomarin acquires Amicus. Final chapter for an incredible orphan disease biotech story. Founded almost 24 years ago, by a parent who made it his personal mission to help his children and others with Pompe (and, over time, other rare diseases) Thank you, John Crowley.
2
2
42
Incredibly positive TYK2 PsO data - 30% PASI100 scores! Nimbus is thrilled to have a partner like Takeda delivering these impressive results with zaso... Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin
takeda.com
Takeda today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a...
2
7
84
Quickly and easily evaluate borrowers' income with our award-winning Income Calculator. Let our technology work harder for you, so you can do great work for your borrowers. Learn more.
4
17
156
Biggest ever https://t.co/GLqV5Ei5qG
#Biotech offerings priced - $TERN $650M at $40/share $GPCR $650M at $65/ADS $KYMR $602M at $86/share $WVE $350M at $19/share $DYN $350M at $18.44/share $VERA $261M at $42.50/share $2.86 Billion!!💥 $XBI
0
0
6
It’s been one of the single largest days for FOPO deal activity in biotech history. Dec 9, 2025. $2.5B+ being raised. 7 deals. Other big days: May 28, 2020. $2.0B. 5 deals May 18, 2020. $2.6B. 6 deals Jan 22, 2020. $1.3B. 7 deals Jan 6, 2016. $1.2B. 9 deals
4
10
85
Oral therapies with biologics-like activity are becoming a reality! KT-621 demonstrates that very deep degradation of STAT6 in the blood and skin of AD patients drives changes in Type-2 biomarkers and clinical endpoints that are in line with, or in many cases numerically
We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6
3
6
57
Newborn birth doses for Hep B vaccinations aren't standard in northwestern Europe (UK, Germany, France, Scandanavia, Holland, etc). They all recommend 8-week vaccinations instead. I know it's a change for the US, where universal birth dose was recommended for decades, but it
endpoints.news
A panel of CDC vaccine advisors has stopped recommending that all children receive the hepatitis B vaccine at birth, overruling scientific consensus and public health officials who pleaded that there...
21
5
66
Sleigh the season with the most personal gift around. Get them a Cameo video!
0
73
896
Amazing journey for Maxwell Freed... See my post from back in 2019... they raised the money to fund a gene therapy, followed a saga thru academia and Taysha... and, despite all that, now Maxwell has been dosed and appears to be responding... Motivated, passionate parents are
endpoints.news
Nationwide Children's Hospital delivers first gene therapy for SLC6A1 disorder to 8-year-old Maxwell Freed, showing early promise in treating seizures and developmental delays.
My friend Amber Freed's son Maxwell has a rare SLC6A2 mutation, linked to severe epilepsy. If you have 6 min, watch her quest to fund a gene therapy for Max: https://t.co/6ohJVFHH5g.
@SLC6A1_Mom Be thankful & wake up every day trying to work on things that make a difference
3
9
80
I've just learned from a Pitchbook report that "AI Native" biotechs have nearly DOUBLE the early clinical success rates of conventional companies! Nearly 90% success! Huuuuuge! I've decided to rebrand all my drug discovery startups that use computers as AI Native from now
23
8
179
Retro Bio is a headscatcher. The lead program is an autophagy enhancer in GLP studies? Earlier programs are iPSCs for Alzheimer's? Raising $1B at a $5B valuation? Holy cow crazy. The probability that this works out for investors is near zero.
Aging startup Retro Bio chases $5 billion valuation
26
12
235
"CMC: A ‘Secret Sauce’ of Biotech Success" - new blog post from Arthur Tzianabos, CEO of Lifordi, on some good CMC learnings, along with a fun personal journey twist. This "boring" part of biotech is critically important! https://t.co/8ABtkoCzct
lifescivc.com
By, Arthur Tzianabos, CEO of Lifordi, as part of the From The Trenches feature of LifeSciVC I often hear biotech leaders refer to their company’s technology and approach in terms of the “secret...
3
7
79
There's much discussion of the current FDA's new posture towards industry... but it's worth noting that some trends have been going on for years... The FDA has been using less & less Advisory Committee meetings for a decade... (data presented in my 2023 Year In Review)
3
3
29
💯
Absolutely horrible day for patients/families with Alzheimer’s…. 1st, GLP-1, now anti-Tau Mab. 2 of more promising approaches. Shows, again, how challenging it is to advance new Rx & why there must be a strong reward for the innovators and investors that deploy risk capital!
1
0
30
Atlas Venture 2025 Year In Review https://t.co/qoUKkkAeAS Been a tough year to pin down as we went from bearish spring to bullish yea end… Listening at 1.25x+ speed is definitely recommended, and moves through the nearly 50-minute presentation slightly faster.
lifescivc.com
This year has truly been a rollercoaster! The markets started off with optimism, but then collapsed into the spring, only to rebound with enthusiasm in recent months. The cadence of M&A has picked...
7
26
181
Beautiful heart-felt new blog post by Nimbus CEO @AbbasRKazimi, capturing the essence of biotech's mission: "Death, Grief, and the Drive to Build Better Therapies"
lifescivc.com
By Abbas Kazimi, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC Hospitals were never meant to be familiar to me, yet for over twenty years MD Anderson became a...
2
3
30
Cidara $CDTX acquired by Merck... Great case study of longevity and reinvention in biotech... founded 13 years ago (2012) and went public in the prolific IPO window of 2015 at $15/share. Even at this $220 takeout price, the 2015 IPO investors are underwater by 30%... as the
2
17
163
Performance incentive unit grants can align CEO compensation to shareholder value creation, rather than simply time-based vesting of new grants. Value has to be created to be earned. Musk needs to create value equivalent to a *new* MSFT + APPL inside of TSLA over the next decade
2
2
55